Clinical trials of linaclotide have shown it to be exceedingly well tolerated, lowering the regulatory burden for investigating the role of GUCY2C signaling in treating obesity. The gene discussed is GUCY2C; the disease is obesity due to melanocortin 4 receptor deficiency.